NCT03588533 - Herzuma-capecitabine/Cisplatin for Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2018

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2021

Conditions

HER-2 Positive Gastric CancerMetastatic Cancer

Interventions

DRUG

Trastuzumab

"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks"

DRUG

Capecitabine

\- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks

DRUG

Cisplatin

\- Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks

Trial Locations (1)

RECRUITING

Dong-A University Hospital, Busan